To explore the molecular mechanisms of osteoarthritis (OA) initiation and progression, global gene expression profiling was performed on cartilage from mice with surgically-induced OA. We used WT mice, and mice lacking ADAMTS-5 activity (ADAMTS-5 Dcat). By comparing the gene expression during OA in these mice we have distinguished early events leading to aggrecan degradation (pre-fibrillated changes) from the downstream progressive phases that follow loss of aggrecan. Methods: Mechanical instability was introduced into 10 week old male mouse knee joints by surgical destabilization of the medial meniscus (DMM). In this model focal degeneration, exemplified by loss of aggrecan in the non-calcified articular cartilage, occurs in the medial tibial plateau 2 weeks after surgery in WT mice. After 6 weeks, aggrecan loss had progressed and cartilage fibrillation was evident. In ADAMTS-5 Dcat mice aggrecan loss and cartilage erosion is significantly reduced. Noncalcified cartilage from the developing lesion in DMM or sham-operated joints at 1, 2 and 6 weeks post-surgery was harvested by laser microdissection. Chondrocyte total RNA was extracted and cRNA generated by linear amplification (MessageAmp, Ambion), labeled with Cy3/Cy5 and hybridized to 44k whole genome microarrays (Agilent). Data was validated by quantitative PCR of selected genes. Results: There was an early upregulation (1 week) in WT mice of cartilage hypertrophy markers, such as collagen X. However in the ADAMTS-5 Dcat mice, these were not upregulated until 6 weeks, suggesting that the hypertrophic response of chondrocytes is not an initiating event, but an event downstream of the onset of ADAMTS-5 activity and/or cartilage degeneration. Of particular interest was the upregulation of the inflammatory mediator Ptgs2 (Cox-2) early (1 and 2 weeks) in WT OA mice. Upregulation of Cox-2 was not seen in ADAMTS-5 Dcat mice. Dysregulation of several Bmps (eg Bmp7), inflammatory cytokines, Fgfs, members of the Wnt/b-catenin pathway were apparent in WT mice. Expression profiling also showed numerous changes in gene expression that followed the same pattern in both WT and ADAMTS-5 Dcat mice, and thus are likely to be independent of ADAMTS-5-mediated aggrecan degradation. These changes include upregulation of several cathepsins (eg cathepsin S), Bmps (eg Bmp7) lumican and fibronectin. Conclusions: This well controlled OA model combined with precise microdissection of cartilage from developing cartilage lesions and microarray technology provides new insights into gene expressed during the initiation and progression of OA. Furthermore the comparison of OA gene expression in WT, ADAMTS-5 Dcat and other mouse models will allow us to prioritize candidate genes for functional analysis.
Purpose: The regulation of in vivo chondrogenesis is incompletely understood, and would be informed by comprehensive analyses of gene expression. So far however, this goal has been limited by an inability to access RNA of sufficient quality from in vivo chondrogenic tissues. In the present study, we set out to generate gene expression profiles representative of key stages of in vivo chondrogenesis. Methods: Tibial and fibular pre-condensed mesenchyme from 11.5dpc Swiss White mouse hindlimbs and the corresponding condensations and cartilage anlagen from 12.5dpc and 13.5dpc mice were micodissected and total RNA isolated using TRIzol. cRNA was generated by linear amplification (MessageAmp, Ambion), labeled with Cy3 or Cy5 and hybridized to 44k whole genome oligo microarrays (Agilent). Microarray data was validated by quantitative PCR of selected genes. Results: We found significant differential expression of 931 genes during these early stages of chondrogenesis. Of these, 380 genes were downregulated and 551 up-regulated. Our studies characterized the expression pattern of gene families previously associated with chondrogenesis, such as adhesion molecules, secreted signalling molecules, transcription factors and extracellular matrix components. Gene ontology approaches identified 892 differentially expressed genes not previously identified during the initiation of chondrogenesis. These included several Bmp, Gdf, Wnt, Sox, Fox, Lhx, Robo and Slit family members. Conclusions: These data represent the first global gene expression profiling analysis of chondrogenic tissues during in vivo development. They identify genes for further study on their functional roles in chondrogenesis, and provide a comprehensive and important resource for future studies on cartilage development, disease, and repair. Purpose: Phase 2 enzyme inducers are recently found to have antiinflammatory activity in addition to its chemopreventive activity. In the current study, we examined the influence of sulforaphan (SFN), one of the most potent inducer of the phase 2 enzymes on the induction of nitric oxide (NO) and prostaglandin (PG) E2 in human articular chondrocytes. The efficacy of SFN on an animal model of osteoarthritis (OA), monoiodoacetate (MIA) induced arthritis in rats was also examined. Methods: Articular cartilages were obtained from knee OA patients and cultured in monolayer. Chondrocytes were stimulated with interleukin (IL)-1 or tumor necrosis factor (TNF)-a with or without 1 hour preincubation with SFN. Production of NO and PGE2 was evaluated by Greiss reaction and enzyme linked immunosorbent assay (ELISA), respectively. The expression of inducible NO synthase and cyclooxygenase (COX)-2 was evaluated by real time reverse transcriptase-polymerase chain reaction and Western blot. Knee joints of rats were injected with 3 mg of MIA and 10 mM of SFN was injected biweekly. The severity of arthritis was evaluated after 1 and 2 weeks by histological grading of articular cartilage in SFN-treated and control animals. Results: SFN significantly inhibited the production of NO and PGE2 induced by either Il-1 or TNF-a dose dependently in monolayer cultured chondrocytes. At the concentration of 10 mM, SFN completely inhibited both NO and COX-2 at mRNA and protein level. SFN treated rats showed significant inhibition of cartilage degradation at 1 week after MIA injection, but at 2 weeks, the difference was not significant between SFN-treated and control rats Conclusions: SFN was found to inhibit NO and PGE2 production in proinflammatory cytokine stimulated chondrocytes and MIA induced rat OA. Delineation of biochemical mechanism regulating cartilage catabolism by SFN may identify potentially safe and effective therapeutic target for inhibition of cartilage degradation in arthritic diseases.
Purpose: Erosive osteoarthritis (EOA) is considered as an aggressive variant of hand OA characterized by a prominent local inflammation and radiographic aspects of central bone erosion on interphalangeal joints. Cytokines, such as Interleukin (IL)-1b and Tumor Necrosis Factor (TNF)a, are involved in the pathophysiology of OA, directly and by stimulation of synoviocytes and chondrocytes to produce inflammatory molecules like nitric oxide (NO), Il-6 and cyclooxygenase (COX)-2. In inflamed joints, NO is involved in joint destruction by enhancing cytokine production and suppressing collagen and proteoglycan synthesis while Il-6 is implicated in bone erosion. Moreover, COX-2 could indirectly affect chondrocytes metabolism by the production of prostaglandins that mediate pain, support the inflammatory process and inhibit aggrecan synthesis. The aim of the present study was to investigate the effects of the TNFaantagonist etanercept on Il-6, COX-2 and iNOS gene expression in human chondrocytes Methods: Primary human chondrocytes were obtained from non-weight bearing articular cartilage of femoral heads after sequential digestions with trypsin and collagenase. Chondrocytes were treated with different
